Results 11 to 20 of about 4,142 (167)

Guselkumab - In Psoriasis and Beyond

Dermatology Practical & Conceptual
Introduction: Guselkumab is an interleukin 23p19 inhibitor, and the first in this group, to be approved by the US Food and Drug Administration (FDA) for the management of moderate to severe psoriasis.
Aditya Kumar Bubna, Vinayak Viplav
doaj   +3 more sources

The effect of guselkumab on inhibiting radiographic progression in patients with active psoriatic arthritis: study protocol for APEX, a Phase 3b, multicenter, randomized, double-blind, placebo-controlled trial

Trials, 2023
Background Guselkumab, a fully human monoclonal antibody targeting the interleukin (IL)-23p19 subunit, is approved to treat adults with active psoriatic arthritis (PsA).
Christopher T. Ritchlin, Laura C. Coates, Philip J. Mease, Désirée van der Heijde, Jiao Song, Yusang Jiang, May Shawi, Alexa P. Kollmeier, Proton Rahman   +8 more
doaj   +1 more source

Rapid Remission of Sunburn-Induced Guttate Psoriasis with Guselkumab

Dermatology and Therapy, 2023
Guselkumab is an anti-interleukin-23 monoclonal antibody that is approved for plaque psoriasis and psoriatic arthritis. We present a case of a 28-year-old female patient with acute onset of guttate psoriasis after a blistering sunburn.
Erin Bartholomew, Bo-Young Chung, Mitchell Davis, Samuel Yeroushalmi, Mimi Chung, Marwa Hakimi, Tina Bhutani, Wilson Liao   +7 more
doaj   +1 more source

Guselkumab Modulates Differentially Expressed Genes in Blood of Patients With Psoriatic Arthritis: Results from Two Phase 3, Randomized, Placebo‐Controlled Trials

ACR Open Rheumatology, 2023
Objective To evaluate gene expression in blood of patients with psoriatic arthritis (PsA) versus healthy controls and identify changes associated with guselkumab treatment.
Stefan Siebert, Kristen M. Sweet, Christopher T. Ritchlin, Elizabeth C. Hsia, Alexa P. Kollmeier, Xie L. Xu, Loqmane Seridi, Qingxuan Song, Sheng Gao, Warner Chen, Michelle Miron   +10 more
doaj   +1 more source

Effect of guselkumab on serum biomarkers in Japanese palmoplantar pustulosis patients in a randomized phase 3 study

JEADV Clinical Practice, 2023
Background It is reported that treatment of palmoplantar pustulosis (PPP) with guselkumab has greater improvement in clinical responses in terms of palmoplantar pustulosis area severity index (PPPASI) score. Here, we present the effect of guselkumab (100
Akimichi Morita, Yanqing Chen, Monica W. L. Leung, Naoko Kawashima, Tadashi Terui   +4 more
doaj   +1 more source

Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-naïve or TNFα inhibitor-experienced

RMD Open, 2021
Objective Evaluation of the efficacy and safety of guselkumab, a human monoclonal antibody targeting the interleukin-23p19 subunit, in patients with psoriatic arthritis (PsA) through 1 year.Methods Adults who met ClASsification criteria for Psoriatic ...
Atul Deodhar, Shihong Sheng, Philip S Helliwell, Soumya D Chakravarty, Elizabeth C Hsia, Enrique R Soriano, Chetan S Karyekar, Wolf-Henning Boehncke, Prasheen Agarwal, Christopher T Ritchlin, Alexa P Kollmeier, Federico Zazzetti, Ramanand A Subramanian, Xie L Xu, Qing C Zuraw, Yusang Jiang, Bei Zhou, Yanli Zhuang, May Shawi   +18 more
doaj   +1 more source

Efficacy and safety of guselkumab and adalimumab for pustulotic arthro-osteitis and their impact on peripheral blood immunophenotypes

Arthritis Research & Therapy, 2022
Objectives We compared the treatment effectiveness between guselkumab and adalimumab in patients with pustulotic arthro-osteitis (PAO). In addition, we performed peripheral blood immunophenotyping to elucidate the immunological background and analyzed ...
Masanobu Ueno, Ippei Miyagawa, Yusuke Miyazaki, Kentaro Hanami, Shunsuke Fukuyo, Satoshi Kubo, Shingo Nakayamada, Yoshiya Tanaka   +7 more
doaj   +1 more source

A non-clinical comparative study of IL-23 antibodies in psoriasis

mAbs, 2021
Four antibodies that inhibit interleukin (IL)-23 are approved for the treatment of moderate-to-severe plaque psoriasis. Here, we present non-clinical data comparing ustekinumab, guselkumab, tildrakizumab and risankizumab with regard to thermostability ...
Li Zhou, Yibing Wang, Qi Wan, Fei Wu, Jeffrey Barbon, Robert Dunstan, Stephen Gauld, Mark Konrad, Laura Leys, Richard McCarthy, Marian Namovic, Christine Nelson, Gary Overmeyer, Denise Perron, Zhi Su, Leyu Wang, Susan Westmoreland, Jun Zhang, Rui Zhu, Geertruida Veldman   +19 more
doaj   +1 more source

Effect of guselkumab on serum biomarkers in patients with active psoriatic arthritis and inadequate response to tumor necrosis factor inhibitors: results from the COSMOS phase 3b study

Arthritis Research & Therapy, 2023
Background Guselkumab is a selective interleukin (IL)-23 inhibitor targeting the IL-23p19 subunit. In the phase 3b COSMOS trial, guselkumab demonstrated efficacy in treating participants with active psoriatic arthritis (PsA) and inadequate response (IR ...
Georg Schett, Warner Chen, Sheng Gao, Soumya D. Chakravarty, May Shawi, Frederic Lavie, Miriam Zimmermann, Mohamed Sharaf, Laura C. Coates, Stefan Siebert   +9 more
doaj   +1 more source

Effectiveness, survival and safety of guselkumab attending to basal characteristics in moderate-to-severe psoriatic patients: a cohort study [version 2; peer review: 2 approved]

F1000Research, 2022
Background: Psoriasis is a chronic inflammatory disease which can impact quality of life. In the past decade multiple biologic treatments have been released with encouraging results. Guselkumab is a monoclonal antibody targeting IL-23p19.
Fiorella Vasquez Chinchay, Manuel Galán-Gutiérrez, Jose C. Armario-Hita, Amalia Pérez-Gil, Ricardo Ruiz-Villaverde, Lourdes Rodriguez-Fernandez-Freire   +5 more
doaj   +1 more source